Should we discontinue one of the HMG‑CoA reductase inhibitors (statins)?

Should We Discontinue Statins?

No, statins should generally not be discontinued in most patients, as discontinuation is consistently associated with increased cardiovascular events, hospitalizations, and all-cause mortality 1, 2. The evidence overwhelmingly demonstrates that stopping statin therapy leads to worse outcomes than continuing treatment.

When Discontinuation May Be Appropriate

Based on guideline recommendations, consider discontinuation only in these specific circumstances 3:

Absolute Contraindications

• Active or chronic liver disease - this is the only absolute contraindication to continued statin use 3

Temporary Discontinuation Scenarios

• Major surgery/perioperative periods - it is prudent to withhold statins during hospitalization for major surgery, as myopathy has developed when patients continued statins during these periods 3
• Symptomatic myopathy with markedly elevated CK (>10 times upper limit of normal) - discontinue immediately 3

Consider Discontinuation in Poor Health Status

• Patients with very limited life expectancy where treatment priorities have fundamentally shifted 4
• Advanced frailty in older adults (especially >85 years) where benefits become questionable 4

Critical Evidence on Discontinuation Risks

The consequences of stopping statins are severe and well-documented:

• Cardiovascular events increase significantly - discontinuation is consistently associated with higher rates of major adverse cardiovascular events 1, 2
• Mortality increases - both cardiovascular and all-cause mortality rise after discontinuation 2, 5
• Worse than never starting - some studies show very low adherence and discontinuation was associated with worse outcomes than never using statins at all 2

Management of Statin-Related Symptoms

Before discontinuing for side effects, attempt rechallenge - this is crucial because most patients who experience statin-related events can tolerate statins long-term 6:

• Of patients rechallenged after a statin-related event, 92.2% were still taking a statin 12 months later 6
• Many statin-related events have other causes, are tolerable, or are specific to individual statins rather than the entire drug class 6

Algorithm for Managing Suspected Statin Intolerance

1. Temporarily discontinue the current statin
2. Evaluate symptoms - determine if truly statin-related
3. Rechallenge with either:
   • The same statin at a lower dose
   • A different statin (as effects may be drug-specific)
4. Monitor carefully with more frequent CK measurements if needed 3

High-Risk Patients Requiring Extra Caution (But Not Discontinuation)

These patients need more careful monitoring but should NOT routinely have statins stopped 3:

• Advanced age (>80 years), especially frail older women
• Small body frame and frailty
• Multisystem disease (chronic renal insufficiency, especially with diabetes)
• Multiple medications/polypharmacy
• Patients on interacting medications (cyclosporine, gemfibrozil, macrolide antibiotics, azole antifungals, cytochrome P-450 inhibitors)

Use lower doses in these populations rather than discontinuing entirely 3.

Proven Benefits That Support Continuation

Statins consistently provide 7:

• 20% reduction in major cardiovascular events (RR 0.72)
• 21% reduction in all-cause mortality (RR 0.79)
• 23% reduction in cardiovascular death (RR 0.77)
• 45% reduction in myocardial infarction (RR 0.55)

These benefits apply to both primary and secondary prevention in patients with chronic kidney disease not requiring dialysis 7.

Common Pitfall to Avoid

Do not discontinue statins based solely on patient-reported muscle symptoms without objective evaluation - the majority of statin-related events can be managed through dose adjustment or switching statins rather than complete discontinuation 6. Educate patients about the cardiovascular risks of stopping therapy 2, 5.